Media ReleasesImugene Limited

View All Imugene Limited News


Quarterly Activities and Cash Flow Report Quarter ended 31 December 2019


Key Highlights:
• Imugene completes oversubscribed placement of $24.6 million to fund clinical programs on 02- December, 2019
• Professor Yuman Fong appointed Chairman of the Oncolytic Virotherapy Scientific Advisory Board along with Dr. Rebecca Auer and Dr. Prasad Adusumilli.
• Completion of Extraordinary General Meeting held on 18-November, 2019 for the acquisition of the oncolytic virus platform developed at the prestigious City of Hope Cancer Research and Treatment Centre in Los Angeles, California.
• Three presentations on Imugene’s B-cell immunotherapy programs (HER-Vaxx, B-Vaxx and PD1-Vaxx) presented at the Annual ESMO Congress in Barcelona , Spain on 1 October 2019.
• Presentation on HER-Vaxx at the European Society for Medical Oncology World Congress Asia in November 2019 in Singapore.
• GMP manufacture of two oncolytic virus constructs (CheckVacc and Vaxinia) completed for Phase I clinical trials scheduled to commence in 2020.

For further information, please download the attached PDF

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?